While Alvotech has underperformed by -5.40%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ALVO fell by -64.25%, with highs and lows ranging from $13.70 to $4.32, whereas the simple moving average fell by -44.05% in the last 200 days.
On December 09, 2025, Barclays started tracking Alvotech (NASDAQ: ALVO) recommending Underweight. A report published by Deutsche Bank on November 04, 2025, Downgraded its rating to ‘Hold’ for ALVO. Morgan Stanley also Upgraded ALVO shares as ‘Overweight’, setting a target price of $14 on the company’s shares in a report dated October 14, 2025. UBS initiated its ‘Buy’ rating for ALVO, as published in its report on February 14, 2025. Barclays’s report from January 29, 2024 suggests a price prediction of $17 for ALVO shares, giving the stock a ‘Overweight’ rating. Citigroup also rated the stock as ‘Neutral’.
Analysis of Alvotech (ALVO)
Further, the quarter-over-quarter increase in sales is 10.55%, showing a positive trend in the upcoming months.
To gain a thorough understanding of Alvotech’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. Taking into account the quick ratio of the company, currently set at 0.74, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and ALVO is recording an average volume of 578.52K. On a monthly basis, the volatility of the stock is set at 6.50%, whereas on a weekly basis, it is put at 7.58%, with a loss of -17.74% over the past seven days. Furthermore, long-term investors anticipate a median target price of $9.02, showing growth from the present price of $4.73, which can serve as yet another indication of whether ALVO is worth investing in or should be passed over.
How Do You Analyze Alvotech Shares?
A leading company in the Drug Manufacturers – Specialty & Generic sector, Alvotech (ALVO) is based in the Luxembourg. When comparing Alvotech shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 20.54, there is a growth in quarterly earnings of 53.97%.
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 63.83%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 5.68% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
